AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review

MT Long, M Noureddin, JK Lim - Gastroenterology, 2022 - Elsevier
Description Nonalcoholic fatty liver disease (NAFLD) is well recognized as a leading
etiology for chronic liver disease, affecting> 25% of the US and global populations. Up to 1 …

Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight

M Eslam, HB El-Serag, S Francque, SK Sarin… - Nature reviews …, 2022 - nature.com
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) affects up to a third of the
global population; its burden has grown in parallel with rising rates of type 2 diabetes …

Non-alcoholic fatty liver disease: Definition and subtypes

SK Han, SK Baik, MY Kim - Clinical and molecular hepatology, 2022 - pmc.ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide, with a global prevalence of approximately 30%. However, the prevalence of …

Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)

S Wang, SL Friedman - Science translational medicine, 2023 - science.org
Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease
that poses a global health threat because of its potential to progress to advanced fibrosis …

the epidemiologic burden of non‐alcoholic fatty liver disease across the world

L Henry, J Paik, ZM Younossi - Alimentary pharmacology & …, 2022 - Wiley Online Library
Background The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing in
parallel with obesity and type 2 diabetes. Aim To review the global epidemiology of NAFLD …

Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis

Q Ye, B Zou, YH Yeo, J Li, DQ Huang, Y Wu… - The lancet …, 2020 - thelancet.com
Background Although non-alcoholic fatty liver disease (NAFLD) is commonly associated
with obesity, it is increasingly being identified in non-obese individuals. We aimed to …

[HTML][HTML] Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis

RS Taylor, RJ Taylor, S Bayliss, H Hagström, P Nasr… - Gastroenterology, 2020 - Elsevier
Background & Aims Biopsy-confirmed liver fibrosis is a prognostic factor for patients with
nonalcoholic fatty liver disease (NAFLD). We performed a systematic review to quantify the …

[HTML][HTML] Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors

O Juanola, S Martínez-López, R Francés… - International journal of …, 2021 - mdpi.com
Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent causes of chronic liver
disease in the Western world, probably due to the growing prevalence of obesity, metabolic …

Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort

TG Simon, B Roelstraete, H Khalili, H Hagström… - Gut, 2021 - gut.bmj.com
Objective Population-based data are lacking regarding the risk of overall and cause-specific
mortality across the complete histological spectrum of non-alcoholic fatty liver disease …

MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease

M Eslam, AJ Sanyal, J George, A Sanyal… - Gastroenterology, 2020 - Elsevier
Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …